Molecular Expression and Diagnosis of Rheumatology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 959

Special Issue Editor


E-Mail Website
Guest Editor
Chung Hwa College of Medical Technology Taiwan, Tainan, Taiwan
Interests: rheumatic diseases; arthritis; molecular expression; molecular diagnosis; molecular mechanism; molecular therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatology is a branch of medicine that focuses on the diagnosis and treatment of conditions and diseases that affect the musculoskeletal system, including joints, bones, muscles, and connective tissues. Molecular expression and diagnosis in rheumatology have advanced significantly in recent years, leading to the improved understanding and management of various rheumatic diseases. Some key aspects of molecular expression and diagnosis in rheumatology include biomarkers, autoantibodies, genetic testing, gene expression profiling, synovial fluid analysis, personalized medicine, and monitoring disease activity. It is important to note that while molecular diagnostics have greatly improved our understanding and management of rheumatic diseases, clinical evaluation and a holistic approach to patient care remain essential. Molecular markers are often used in conjunction with clinical assessments to provide a comprehensive view of a patient's condition. This Special Issue aims to compile studies related to new molecular diagnostics, mechanisms, and therapeutics in rheumatology. We welcome original research articles, short communications, and reviews and look forward to receiving your contributions.

Dr. Shih-Yao Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatology
  • rheumatic diseases
  • molecular diagnostics
  • molecular mechanisms
  • molecular therapeutics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 760 KiB  
Review
Role of Myostatin in Rheumatoid Arthritis: A Review of the Clinical Impact
by Fabiola Gonzalez-Ponce, Melissa Ramirez-Villafaña, Eli Efrain Gomez-Ramirez, Ana Miriam Saldaña-Cruz, Sergio Gabriel Gallardo-Moya, Norma Alejandra Rodriguez-Jimenez, Heriberto Jacobo-Cuevas, Cesar Arturo Nava-Valdivia, Felipe Alexis Avalos-Salgado, Sylvia Totsuka-Sutto, Ernesto German Cardona-Muñoz and Edgar Ricardo Valdivia-Tangarife
Diagnostics 2024, 14(11), 1085; https://doi.org/10.3390/diagnostics14111085 - 23 May 2024
Viewed by 702
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects synovial joints and that frequently involves extra-articular organs. A multiplicity of interleukins (IL) participates in the pathogenesis of RA, including IL-6, IL-1β, transforming growth factor-beta (TGF-β), and tumor necrosis factor (TNF)-α; immune cells [...] Read more.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects synovial joints and that frequently involves extra-articular organs. A multiplicity of interleukins (IL) participates in the pathogenesis of RA, including IL-6, IL-1β, transforming growth factor-beta (TGF-β), and tumor necrosis factor (TNF)-α; immune cells such as monocytes, T and B lymphocytes, and macrophages; and auto-antibodies, mainly rheumatoid factor and anti-citrullinated protein antibodies (ACPAs). Skeletal muscle is also involved in RA, with many patients developing muscle wasting and sarcopenia. Several mechanisms are involved in the myopenia observed in RA, and one of them includes the effects of some interleukins and myokines on myocytes. Myostatin is a myokine member of the TGF-β superfamily; the overproduction of myostatin acts as a negative regulator of growth and differentiates the muscle fibers, limiting their number and size. Recent studies have identified abnormalities in the serum myostatin levels of RA patients, and these have been found to be associated with muscle wasting and other manifestations of severe RA. This review analyzes recent information regarding the relationship between myostatin levels and clinical manifestations of RA and the relevance of myostatin as a therapeutic target for future research. Full article
(This article belongs to the Special Issue Molecular Expression and Diagnosis of Rheumatology)
Show Figures

Figure 1

Back to TopTop